Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2019 09:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2019 Financial Results

EXTON, Pa., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
August 06, 2019 16:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera to Release 2019 Second Quarter Results on August 8, 2019

EXTON, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
July 23, 2019 07:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and John J. Kirby as Chief Financial Officer

EXTON, Pa., July 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and the promotion...
June 18, 2019 16:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals to Present at the 2019 JMP Securities Life Sciences Conference

EXTON, Pa., June 18, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 2019 JMP Securities Life Sciences Conference on...
May 02, 2019 16:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

EXTON, Pa., May 02, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
April 10, 2019 07:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Provides Corporate Update

EXTON, Pa., April 10, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
April 02, 2019 07:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Presents ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting

EXTON, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
March 06, 2019 16:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update

– ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 –– ILLUMINATE-204 Enrollment Complete; Data Anticipated Q4 2019 –– ILLUMINATE-206 Trial Expected to Initiate Q2 2019 –– Chief Medical...
February 27, 2019 07:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment

- Results from the Phase 2 Expansion of ILLUMINATE-204 anticipated to be reported in the 4th Quarter of 2019 – - December 2018 Interim Update of 34 efficacy evaluable patients demonstrated 32.4%...
January 04, 2019 07:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

EXTON, Pa., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference on...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right